PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: PF-04494700 - Low Dose ArmDrug: PF-04494700 - High Dose ArmDrug: Placebo Comparator
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT00141661
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Memphis, Tennessee, United States
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2010-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00141167
- Locations
- ๐จ๐ณ
Pfizer Investigational Site, Taipei, Taiwan
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1005
- Registration Number
- NCT00141206
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Morgantown, West Virginia, United States
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.
Phase 3
Completed
- Conditions
- Pain
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 325
- Registration Number
- NCT00141362
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Phase 2
Completed
- Conditions
- Epilepsy, Partial
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00141414
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Bonn, Germany
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 325
- Registration Number
- NCT00141245
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, York, United Kingdom
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Phase 3
Completed
- Conditions
- Seizure Disorder, Partial
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 750
- Registration Number
- NCT00141336
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Toronto, Ontario, Canada
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
Phase 4
Completed
- Conditions
- HIV InfectionHepatitis C
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00141284
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Toronto, Ontario, Canada
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
Phase 4
Completed
- Conditions
- Ocular HypertensionGlaucoma, Open-Angle
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 329
- Registration Number
- NCT00140062
- Locations
- ๐ธ๐ช
Pfizer Investigational Site, Uppsala, Sweden
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 410
- Registration Number
- NCT00139698
- Locations
Pfizer Investigational Site
ยฉ Copyright 2025. All Rights Reserved by MedPath